P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE.

HemaSphere

COATES T., LAL A., BROWN R., KALFA T., KWIATKOWSKI J., BREVARD J., TRENOR C., WOOD K., SHETH S.. P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere. 2022 Aug 1; 6(Suppl):43-44.

2022

https://researcherprofiles.org/profile/425025952

COATES T., LAL A., BROWN R., KALFA T., KWIATKOWSKI J., BREVARD J., TRENOR C., WOOD K., SHETH S.

Northern California Comprehensive Thalassemia Center

Search form

You are here

P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE.